Arch. Pharm. Chem. Life Sci. 2016, 349, 466–474
Maleimide Containing Tricyclo Anthracene Derivatives
ARC HH PHARM
Archiv der Pharmazie
[
[
19] C. T. Supuran, Curr. Pharm. Des. 2010, 16, 3233–3245.
20] S. G o€ ksu, A. Naderi, Y. Akbaba, P. Kalın, A. Akıncıo gꢁ lu, I.
Gulcin, S. Durda gꢁ i, R. E. Salmas, Bioorg. Chem. 2014, 56,
[45] J. Y. Winum, A. Scozzafava, J. L. Montero, C. T. Supuran,
Anticancer Agents Med. Chem. 2009, 9, 693–702.
[46] S. Pastorekova, M. Zatovicova, J. Pastorek, Curr. Pharm.
Des. 2008, 14, 685–698.
_
75–82.
[
21] A. Akıncıo gꢁ lu, H. Akıncıo gꢁ lu, I. G u€ l cS in, S. Durda gꢁ ı, C. T.
[47] J. Y. Winum, M. Rami, A. Scozzafava, J. L. Montero, C. T.
Supuran, Med. Res. Rev. 2008, 28, 445–463.
[48] O. O. Guler, G. De Simone, C. T. Supuran, Curr. Med.
Chem. 2010, 17, 1516–1526.
[49] G. De Simone, C. T. Supuran, Biochim. Biophys. Acta.
2010, 1804, 404–409.
[50] S. Pastorekova, J. Pastorek, Cancer-related carbonic
anhydrase isozymes and their inhibition; in Carbonic
Anhydrase. Its Inhibitors and Activators, CRC Press, 2004,
pp. 255–281.
Supuran, S. G o€ ksu, Bioorg. Med. Chem. 2015, 23,
3
592–3602.
_
[
[
[
[
22] I. G u€ l cS in, S. Beydemir, Mini Rev. Med. Chem. 2013, 13,
4
08–430.
_
23] SS . Beydemir, I. G u€ l cS in, J. Enzyme Inhib. Med. Chem. 2004,
19, 193–197.
_
€ _
ꢁ
24] M. SS ent u€ rk, I. G u€ l cS in, SS . Beydemir, O. I. K u€ frevioglu, C. T.
Supuran, Chem. Biol. Drug Des. 2011, 77, 494–499.
25] C. T. Supuran, A. Scozzafava, A. Casini, Med. Res. Rev.
2003, 23, 146–189.
[51] O. Tureci, U. Sahin, E. Vollmar, S. Siemer, E. G o€ ttert, G.
[
[
26] C. T. Supuran, Mol. Divers. 2011, 15, 305–316.
27] B. Arabaci, I. G u€ l cS in, S. Alwasel, Molecules 2014, 19,
Seitz, A. K. Parkkila, G. N. Shah, J. H. Grubb, M.
Pfreundschuh, W. S. Sly, Proc. Natl. Acad. Sci. 1998, 95,
7608–7613.
_
10103–10114.
[
28] A. M. Alafeefy, S. Isik, H. A. Abdel-Aziz, A. E. D. Ashour,
D. Vullo, N. A. Al-Jaber, C. T. Supuran, Bioorg. Med.
Chem. 2013, 21, 1396–1403.
[52] Y. Lou, P. C. McDonald, A. Oloumi, S. Chia, C. Ostlund, A.
Ahmadi, A. Kyle, U. Aufdem Keller, S. Leung, D.
Huntsman, B. Clarke, B. W. Sutherland, D. Waterhouse,
M. Bally, C. Roskelley, C. M. Overall, A. Minchinton, F.
Pacchiano, F. Carta, A. Scozzafava, N. Touisni, J. Y.
Winum, C. T. Supuran, S. Dedhar, Cancer Res. 2011, 71,
3364–3376.
[53] T. Fiaschi, E. Giannoni, M. L. Taddei, P. Cirri, A. Marini, G.
Pintus, C. Nativi, B. Richichi, A. Scozzafava, F. Carta, E.
Torre, C. T. Supuran, P. Chiarugi, Cell Cycle 2013, 12,
1791–1801.
[
[
[
29] C. T. Supuran, J. Enzyme Inhib. Med. Chem. 2012, 27,
7
59–772.
30] D. Neri, C. T. Supuran, Nat. Rev. Drug. Discov. 2011, 10,
67–777.
31] S. Pastorekova, S. Parkkila, J. Pastorek, C. T. Supuran, J.
Enzyme Inhib. Med. Chem. 2004, 19, 199–229.
7
[
[
32] C. T. Supuran, Future Med. Chem. 2011, 3, 1165–1180.
33] H. G o€ cS er, Y. CS etinkaya, S. G o€ ksu, I. G u€ l cS in, C. T. Supuran,
_
J. Enzyme Inhib. Med. Chem. 2015, 30, 316–320.
34] Y. CS etinkaya, H. G o€ cS er, I. G u€ l cS in, A. Menzek, Arch. Pharm.
[54] A. McIntyre, S. Patiar, S. Wigfield, J. Li, I. Ledaki, H.
Turley, R. Leek, C. Snell, K. Gatter, W. S. Sly, R. D.
Vaughan-Jones, P. Swietach, A. L. Harris, Clin. Cancer
Res. 2012, 18, 3100–3111.
_
[
[
2
014, 347, 354–361.
35] A. Akıncıo gꢁ lu, M. Topal, I. G u€ l cS in, S. G o€ ksu, Arch. Pharm.
014, 347, 68–76.
_
_
̈
2
[55] P. Taslimi, I. Gulc i̧ n, N. Oztas ķ ın, Y. Çetinkaya S. Goksu, S.
̈
̈
[
[
36] R. G. Khalifah, J. Biol. Chem. 1971, 246, 2561–2573.
37] M. D’Ascenzio, S. Carradori, C. De Monte, D. Secci, M.
Ceruso, C. T. Supuran, Bioorg. Med. Chem. 2014, 22,
H. Alwasel, C. T. Supuran, J. Enzyme Inhib. Med. Chem.
2016, 31, 603–607.
[56] R. Opavsk ꢂy , S. Pastorekov aꢂ , V. Zeln ꢂı k, A. Gibadulinov aꢂ , E.
J. Stanbridge, J. Z aꢂ vada, R. Kettmann, J. Pastorek,
1821–1831.
_
[
38] F. Topal, M. Topal, H. Gocer, P. Kalın, U. M. Ko cS yi gꢁ it, I.
Genomics 1996, 33, 480–487.
G u€ l cS in, S. H. Alwasel, J. Enzyme Inhib. Med. Chem. 2016,
[57] J. Zavada, Z. Z aꢂ vadov aꢂ , J. Pastorek, Z. Biesov aꢂ , J. Jezek, J.
3
1, 674–683.
Velek, Br. J. Cancer 2000, 82, 1808–1813.
[58] H. Gocer, A. Aslan, I. G u€ l cS in, C. T. Supuran, J. Enzyme
Inhib. Med. Chem. 2016, 31, 503–507.
[59] A. Thiry, J. M. Dogne, B. Masereel, C. T. Supuran, Trends
Pharmacol. Sci. 2006, 27, 566–573.
[60] C. T. Supuran, Carbonic anhydrases: catalytic and
inhibition mechanisms, distribution and physiological
roles; in Carbonic Anhydrase. Its Inhibitors and Activa-
tors, CRC Press, 2004, pp. 1–23.
_
[
39] K. J. Borthwick, N. Kandemir, R. Topaloglu, U. Kornak, A.
Bakkaloglu, N. Yordam, S. Ozen, H. Mocan, G. N. Shah,
W. S. Sly, F. E. Karet, J. Med. Genet. 2003, 40, 115–121.
40] C. De Monte, S. Carradori, D. Secci, M. D’Ascenzio, D.
Vullo, M. Ceruso, Eur. J. Med. Chem. 2014, 84, 240–246.
[
[
[
41] A. Akdemir, O. Guzel-Akdemir, A. Scozzafav, C. Capasso,
̈
C. T. Supuran, Bioorg. Med. Chem. 2013, 21, 5228–5232.
42] S. Pastorekova, D. Vullo, A. Casini, A. Scozzafava, J.
Pastorek, I. Nishimori, C. T. Supuran, J. Enzyme Inhib.
Med. Chem. 2005, 20, 211–217.
43] H. M. Said, C. Hagemann, F. Carta, A. Katzer, B. Polat, A.
Staab, A. Scozzafava, J. Anacker, G. H. Vince, M. Flentje,
C. T. Supuran, Bioorg. Med. Chem. 2013, 21, 3949–3857.
44] A. Thiry, J. M. Dogne, B. Masereel, Trends Pharmacol. Sci.
_
[61] A. Scozzafava, M. Passaponti, C. T. Supuran, I. G u€ l cS in, J.
Enzyme Inhib. Med. Chem. 2015, 30, 586–591.
€
_
[
[62] H. G o€ cS er, A. Akıncıo gꢁ lu, N. Ozta sS kın, S. G o€ ksu, I. G u€ l cS in,
Arch. Pharm. 2013, 346, 783–792.
[63] R. Bonnett, G. Martinez, Org. Lett. 2002, 4, 2013–2016.
[64] H. S. Lee, J. S. Yu, C. K. Lee, Magn. Reson. Chem. 2009, 47,
711–715.
[
2006, 27, 566–573.
ß 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com
473